High-dose enzymes ‘might prevent NAFLD post-Whipple’
And if the condition develops, raising the dose improves it, researchers show
The use of high-dose digestive enzymes is associated with a reduced incidence of nonalcoholic fatty liver disease (NAFLD) following pancreaticoduodenectomy compared with normal-dose enzyme replacement, a trial shows.
Between 8% and 37% of patients develop NAFLD after the surgery, also known as a Whipple procedure. Patients commonly receive a digestive-enzyme preparation after Whipple, to compensate for the reduction in exocrine pancreatic capacity, the Japanese authors said.
